Economic evaluations of perioperative use of hemocoagulase bothrops atrox:a real-world based study
OBJECTIVE To evaluate the economics of hemocoagulase bothrops atrox for injection(HCB).METHODS The cost and efficacy data of hospitalized patients were collected retrospectively from 40 tertiary medical institutions across 22 domestic provinces during March 2023.The subjects were assigned into three groups of HCB,hemocoagulase agkistrodon for injection(HA)and lyophilizing thrombin powder(LT).Propensity score method(PSM)was utilized for matching the baseline profiles.Economic analysis was conducted by cost minimization and cost-effectiveness.RESULTS No difference existed in dis-charge outcome among three groups.However,HCB exhibited significantly shorter hospitalization days than HA/LT(HCB group vs.HA group:9.304 d vs.10.62d,P＜0.01;HCB group vs.LT group:9.336 d vs.11.02 d,P＜0.01).Additionally,total hospitalization cost per capita was lower in HCB than HA/LT(HCB group vs.HA group:¥32 148 vs.¥38 114,P＜0.01;HCB group vs.LT group:¥35 957 vs.¥59 992,P＜0.01).As compared with HA,cost of hemocoagulase preparation declined in HCB(¥342.54 vs.¥426.56,P＜0.01).No difference existed in cost of hemocoagulase preparation between HCB and LT.CONCLUSION HCB is more cost-effective than LT/HA in perioperative period.
hemocoagulase bothrops atrox for injectionperioperativepharmacoeconomicsreal world
NETL
NSTL
万方数据
